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NRAS Mutation Is the Sole Recurrent Somatic
Mutation in Large Congenital Melanocytic Nevi
Christelle Charbel1,2, Romain H. Fontaine1,2,13, Gabriel G. Malouf2,3,13, Arnaud Picard2,4, Natacha Kadlub2,4,
Nizar El-Murr1,2, Alexandre How-Kit5, Xiaoping Su6, Aurore Coulomb-L’Hermine2,7, Jorg Tost5,8,
Samia Mourah9, Selim Aractingi1,10,11,14 and Sarah Gue´gan1,2,12,14
Congenital melanocytic nevus (CMN) is a particular melanocytic in utero proliferation characterized by an
increased risk of melanoma transformation during infancy or adulthood. NRAS and BRAF mutations have
consistently been reported in CMN samples, but until recently results have been contradictory. We therefore
studied a series of large and giant CMNs and compared them with small and medium CMNs using Sanger
sequencing, pyrosequencing, high-resolution melting analysis, and mutation enrichment by an enhanced version
of ice-COLD-PCR. Large–giant CMNs displayed NRAS mutations in 94.7% of cases (18/19). At that point, the role of
additional mutations in CMN pathogenesis had to be investigated. We therefore performed exome sequencing
on five specimens of large–giant nevi. The results showed that NRAS mutation was the sole recurrent somatic
event found in such melanocytic proliferations. The genetic profile of small–medium CMNs was significantly
different, with 70% of cases bearing NRAS mutations and 30% showing BRAF mutations. These findings strongly
suggest that NRAS mutations are sufficient to drive melanocytic benign proliferations in utero.
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INTRODUCTION
Congenital melanocytic nevus (CMN) is a benign clonal
melanocytic proliferation that develops in utero. CMN is
classified by its projected adult size (PAS), may be associated
with neurocutaneous melanosis (DeDavid et al., 1996),
and moreover exhibits a risk of melanoma transformation.
Indeed, prospective studies have reported a rate of 4–5% of
melanomas in patients with CMNs 420 cm PAS after 5 years
(Ruiz-Maldonado et al., 1992; Marghoob et al., 1996). The risk
of melanomas appears proportional to the lesion size, reaching
up to a 10–15% risk for lesions 440 cm in diameter (Krengel
et al., 2006). Neurological abnormalities, numerous satellite
nevi, and a truncal location are also reported in patients with
CMNs 440 cm PAS (Hale et al., 2005; Bett, 2006). On the
other hand, familial cases of CMNs have only rarely been
reported (Frieden and Williams, 1994; de Wijn et al., 2010).
CMN does not follow a Mendelian pattern and is rather
considered to be the consequence of a causative somatic
mutation. CMNs have consistently been reported to harbor
NRAS and BRAF mutations (Papp et al., 1999, 2005; Ichii-
Nakato et al., 2006; Bauer et al., 2007; Dessars et al., 2009; Qi
et al., 2011; Wu et al., 2011). Several studies have described
NRAS mutations in CMNs (Bauer et al., 2007; Dessars et al.,
2009; Wu et al., 2011; Kinsler et al., 2013), whereas others
detected the presence of BRAF mutations (Papp et al., 1999,
2005; Wu et al., 2007; Qi et al., 2011). In view of these
discrepancies, we aimed to study NRAS and BRAF mutations
in our series of CMNs using different powerful sequencing
techniques. Moreover, in melanomagenesis, NRAS mutations
are known to lead to transformation by cooperating with other
genetic events. Similarly, additional mutations may intervene
in CMN pathogenesis. In order to answer the question of
other pathways involved in CMN, we performed unbiased
next-generation whole-exome sequencing using large CMNs
and matched control blood specimens.
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RESULTS
NRAS mutations in large and giant CMNs analyzed by four
different sequencing techniques
A total of 19 patients diagnosed with large or giant CMNs
were included in the study. The clinical characteristics are
reported in Table 1. The median age of the patients was
8 months (range, 2–60 months). The male/female sex ratio
was 0.73 (8 males/11 females). All body localizations were
represented: 7 of 19 nevi (36.9%) involved the head, 8 of
19 nevi (42.1%) involved the arm and/or trunk, and 4 of 19
(21%) the legs. Neurological symptoms were found in none of
the 19 patients; ultrasonographic evaluations and magnetic
resonance images were normal in all patients who underwent
such examinations. No history of familial CMN was recorded
in any patient.
DNA samples were processed using three standard techni-
ques. NRAS and BRAF mutations were screened using Sanger
sequencing. Mutations in NRAS exon 3 were also assessed
using pyrosequencing and high-resolution melting (HRM)
analysis in order to further improve the sensitivity of mutation
detection. Using these three techniques, only one large CMN
harbored a BRAF mutation. We showed that 16 large or giant
CMNs bore an NRAS mutation, with 8 c.181C4A, p.Q61K
mutations and 8 c.182A4G, p.Q61R mutations. Two nevi
(patients 7 and 12) displayed neither BRAF nor NRAS muta-
tions (Table 2).
A minor NRAS clone could still remain undetectable at this
stage. To definitely solve this question, we harvested addi-
tional specimens (from 4 other areas for patient 12) as well as
performed enhanced version of ice-COLD-PCR (E-ice-COLD-
PCR; for patients 7 and 12). This technique relies on a
chemically modified, nonextendable oligonucleotide comple-
mentary to the wild-type (WT) allele sequences that blocks
amplification of WT alleles and thereby ‘‘enrich’’ mutated
alleles. These mutated alleles were subsequently analyzed
by pyrosequencing. Interestingly, a clonal NRAS Q61R
mutation was found by E-ice-COLD-PCR in both of these
large CMNs (patients 7 and 12). Therefore, this high-sensitivity
sequencing technique detected NRAS mutations in two
large CMNs (10.5%) previously classified as BRAF and NRAS
WT using standard techniques. Overall, an NRAS mutation
was detected in 94.7% of large or giant CMNs (18/19); 8 out
of 19 nevi (42.1%) bore the c.181C4A, p.Q61K muta-
tion whereas 10 out of 19 nevi (52.6%) displayed the
c.182A4G, p.Q61R mutation. Finally, one large CMN
(patient 9) harbored a BRAF mutation without any NRAS
mutation. Of note, the first sample of patient 12 nevus did
not display a BRAF or NRAS mutation even using E-ice-
COLD-PCR. However, when four additional nevus areas
(specimens) were selected and screened, two out of four
revealed the presence of a c.182A4G, p.Q61R NRAS
mutated clone.
Table 1. Clinical characteristics of the 19 large and giant CMNs









1 3.5 Years Female Head 420–30 Giant No No Compound
2 5 Years Female Arm 420–30 Giant No No Compound
3 2 Months Female Leg 410–20 Large No No Compound
4 19 Months Male Arm 410–20 Large No No Compound
5 21 Months Female Leg 410–20 Large No No Compound
6 5 Years Male Head 410–20 Large No ND Compound
7 3 Months Male Trunk 410–20 Large ND ND Compound
8 7 Months Male Trunk 440–60 Giant No ND Compound
9 25 Months Male Leg 410–20 Large No No Compound
10 4 Months Male Head 410–20 Large No No Compound
11 4 Months Female Trunk 420–30 Giant No ND Compound
12 5 Months Female Head 410–20 Large No No Compound
13 9 Months Female Head 420–30 Giant No No Dermal
14 13 Months Male Head 410–20 Large No No Compound
15 3 Months Male Head 420–30 Giant ND ND Compound
16 8 Months Female Arm 410–20 Large No ND Compound
17 6 Months Female Arm 420–30 Giant No No Compound
18 4 Months Female Trunk 410–20 Large No No Dermal
19 9 Months Female Leg 410–20 Large No No Compound
Abbreviations: CMN, congenital melanocytic nevus; NCM, neurocutaneous melanosis; ND, nondetermined; PAS, projected adult size.
1Classification by PAS as defined in Ruiz-Maldonado (2004).
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NRAS mutation as the sole recurrent somatic mutation
confirmed by whole-exome sequencing of large and giant CMNs
We asked therefore whether additional mutations beside
NRAS were needed to drive CMN pathogenesis. To answer
this question, we selected DNA from five patients with large or
giant CMNs with matched nontumor peripheral blood DNA
available. Whole-exome sequencing was performed on these
five sample pairs in order to detect somatic mutations in the
nevi (Table 3). Median coverage of the exome sequencing
was 54 (range, 51–60). Analysis revealed a total of nine
somatic nonsynonymous mutations involving eight genes. As
expected, 4 of the 5 tumors harbored the previously confirmed
NRAS mutation (patients 6, 14, 15, and 16). Visual inspection
of the reads did not identify any other mutations in the vicinity
of the NRAS Q61 mutation. We also evaluated the percentage
of mutated cells within a nevus harboring the NRAS mutation.
It ranged from 10 to 40% in these 4 patients analyzed using
whole-exome sequencing: 25% in patient 6 (13 mutated/51
nonmutated tags), 10% in patient 14 (8 mutated/86 non-
mutated tags), 40% in patient 15 (22 mutated/55 nonmutated
tags), and 19% in patient 16 (14 mutated/74 nonmutated tags).
Interestingly, patient 12 nevus, which revealed a NRAS
mutated subclone only after an extensive screening using
E-ice-COLD-PCR sequencing of several areas, displayed
1 mutated tag of NRAS out of 79 tags in the nevus versus
no identified mutated tag in matched blood DNA (number of
total tags detected 64). Therefore, both E-ice-COLD-PCR and
exome sequencing techniques led to corresponding results.
Besides NRAS, and using our criteria (3 mutated tags in nevus,
and a total of 10 tags covered in nevus and normal at
minimum), exome sequencing revealed the presence of
seven other non-NRAS, non-BRAF, nonsynonymous mutations
Table 2. Genetic characteristics of the 19 large and giant CMNs
NRAS exon 3
Patient Sanger Pyrosequencing HRM1 E-ice-COLD-PCR
1 WT WT NRAS3 mutated NRAS3 Q61K
2 NRAS3 Q61R NRAS3 mutated NRAS3 mutated
3 NRAS3 Q61K NRAS3 mutated NRAS3 mutated
4 NRAS3 Q61R NRAS3 mutated NRAS3 mutated
5 NRAS3 Q61K NRAS3 mutated NRAS3 mutated
6 NRAS3 Q61K NRAS3 mutated NRAS3 mutated
7 ND WT WT NRAS3 Q61R
8 NRAS3 Q61R NRAS3 mutated NRAS3 mutated
9 BRAF V600E WT WT
10 NRAS3 Q61R NRAS3 mutated NRAS3 mutated
11 NRAS3 Q61K NRAS3 mutated NRAS3 mutated
12 WT WT WT NRAS3 Q61R
13 NRAS3 Q61R NRAS3 mutated NRAS3 mutated
14 NRAS3 Q61R NRAS3 mutated NRAS3 mutated
15 NRAS3 Q61K NRAS3 mutated NRAS3 mutated
16 NRAS3 Q61K NRAS3 mutated NRAS3 mutated
17 NRAS3 Q61R NRAS3 mutated NRAS3 mutated
18 NRAS3 Q61R NRAS3 mutated NRAS3 mutated
19 NRAS3 Q61K NRAS3 mutated NRAS3 mutated
Abbreviations: CMN, congenital melanocytic nevus; E-ice-COLD-PCR, enhanced version of ice-COLD-PCR; HRM, high-resolution melting analysis;
ND, nondetermined; WT, wild type.
1High-resolution melting analysis. Sanger sequencing was used to screen NRAS exon 2 and 3 and BRAF exon 15 mutations. Pyrosequencing and high-
resolution melting analysis were used to screen NRAS exon 2 and 3 mutations. Enhanced-ice-COLD-PCR was used to screen NRAS exon 3 mutation.
Table 3. Results of whole-exome sequencing of five CMN samples and matched blood DNA
Gene Chr cDNA shift Peptide shift SIFT prediction Patient 6 Patient 12 Patient 14 Patient 15 Patient 16
NRAS 1 SNP c.181C4A p.Q61K Damaging 1 0 0 1 1
NRAS 1 SNP c.182A4G p.Q61R Damaging 0 0 1 0 0
Abbreviations: cDNA, complementary DNA; CMN, congenital melanocytic nevus; SNP, single-nucleotide polymorphism.
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involving BAGE5, C5orf42, EPS15, ETV2, KRT77, NKIRAS2,
and TRPV4. At this stage, we had to confirm whether these
results corresponded to real mutations or to nonreproducible
artifacts. Using two different sequencing techniques, i.e.,
Sanger sequencing (Supplementary Table S1 online) and a
sensitive allele-specific PCR approach, we failed to confirm
the presence of these mutations, suggesting that they corre-
sponded to false positives of the technique. Therefore, NRAS
mutation appears to be the sole recurrent somatic mutation
identified in large and giant CMNs.
Mixed pattern of NRAS and BRAF mutations in small and
medium CMNs
A second group of smaller CMNs was compared with the
previous group of CMNs: 20 patients diagnosed with small or
medium CMNs were also studied. The median age of the
patients was 50 months, whereas the mean age was 35
months. The male/female sex ratio was 0.67 (8 males/12
females). All body localizations were represented: 5 of 20 nevi
(25%) involved the head, 10 of 20 nevi (50%) involved the
arm and/or trunk, and 5 of 20 (25%) the leg. Therefore, in
terms of sex ratio and body localization of nevi, both groups
were comparable.
Small and medium CMNs were analyzed for NRAS and
BRAF mutations using the various techniques previously
described: Sanger sequencing, pyrosequencing, HRM ana-
lysis, and mutation enrichment by E-ice-COLD-PCR (Table 4).
An NRAS mutation was detected in 14 out of 20 (70%) small–
medium CMN: 8 nevi (40%) bore the c.181C4A, p.Q61K
mutation and 6 nevi (30%) bore the c.182A4G, p.Q61R
mutation. A total of 30% (6/20) of small–medium CMNs
harbored a BRAF mutation. Therefore, the mutational profile
of these nevi was different from the large CMN mutational
profile, with a lower percentage of NRAS mutations and a
higher percentage of BRAF mutations. Of note, only 5 NRAS
mutated nevi (25%) were detected using the three conventional
techniques. The high-sensitivity sequencing technology showed
low-frequency mutated clones in small–medium lesions as it
revealed NRAS mutations in 9 nevi (45%) previously classified
as NRAS WT using standard technologies, whereas this was the
case in only 2 large CMNs (10.5%).
DISCUSSION
NRAS is one of the three major isoforms of the RAS family of
GTPases proteins. Through the downstream activation of four
major signaling pathways mitogen-activated protein kinase,
Table 4. Clinical and genetic characteristics of the 20 small and medium CMNs
Sample Age Sex Tissue site PAS (cm) Histological features Sequencing1 E-ice-COLD-PCR
20 35 Months Female Arm 1.5–10 Compound WT NRAS3 Q61K
21 4 Months Female Head 1.5–10 Compound NRAS3 Q61R
22 10 Months Male Arm 1.5–10 Compound NRAS3 Q61R
23 16 Years Female Leg 1.5–10 Dermal NRAS3 Q61K
24 11 Months Male Head 1.5–10 Compound WT NRAS Q61R
25 9 Months Female Trunk 1.5–10 Compound BRAF V600E NRAS3 WT
26 16 Months Female Head 1.5–10 Compound WT NRAS3 Q61R
27 44 Months Male Trunk 1.5–10 Compound ND NRAS3 Q61K
28 12 Years Male Head 1.5–10 Compound BRAF V600E NRAS3 WT
29 38 Months Female Arm 1.5–10 Compound WT NRAS3 Q61K
30 8.5 Years Female Trunk 1.5–10 Compound BRAF V600E
31 6 Years Female Arm 1.5–10 Compound NRAS3 Q61K NRAS3 Q61K
32 16 Months Male Leg 1.5–10 Compound BRAF V600E
33 5 Years Female Leg 1.5–10 Compound WT NRAS3 Q61R
34 10 Years Male Head o1.5 Compound BRAF V600E
35 4 Months Female Arm 1.5–10 Compound BRAF V600E
36 22 Months Female Trunk 1.5–10 Compound WT NRAS3 Q61K
37 6 Years Female Leg 1.5–10 Compound ND NRAS3 Q61K
38 33 Months Male Leg 1.5–10 Compound WT NRAS3 Q61R
39 7 Months Male Trunk 1.5–10 Compound NRAS3 Q61K NRAS3 Q61K
Abbreviations: CMN, congenital melanocytic nevus; E-ice-COLD-PCR, enhanced version of ice-COLD-PCR; ND, nondetermined; PAS, projected adult size;
WT, wild type.
Mutation enrichment by enhanced-ice-COLD-PCR was used to screen NRAS exon 3 mutations.
1Sanger sequencing was used to screen NRAS exon 2 and 3 and BRAF exon 15 mutations followed by pyrosequencing and high-resolution melting analysis in
order to screen NRAS exon 2 and 3 mutations.
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phosphatidylinositide 3 kinase, phospholipase C/protein
kinase C, and RalGDS, NRAS is involved in cell growth. All
reported NRAS gene mutations occur in exon 2 or exon 3,
with 65% of mutations occurring in exon 3 at codon 61. The
most frequent amino acid substitutions are Q61K and Q61R
(Takata and Saida, 2006). These substitutions result in a
constitutively active NRAS protein, unable to cleave
guanosine triphosphate.
Using an unbiased series of patients, we found the presence
of NRAS mutations in 94.7% and 70% of large–giant and
small–medium CMN cases, respectively. NRAS mutations
have been detected at low percentage in malignant melanoma
as well as in acquired melanocytic nevi (Poynter et al., 2006).
However, NRAS mutations have been closely associated with
CMNs. Previous studies detected variable levels of NRAS
mutation in CMNs. These vary between 22 and 80% in
affected cutaneous and neurological tissues of patients (Carr
and Mackie, 1994; Ichii-Nakato et al., 2006; Dessars et al.,
2009; Wu et al., 2011; Kinsler et al., 2013). In view of these
differences, our study confirms that CMNs display a high
incidence of NRAS mutations, highlighting the role of this
pathway in the disease.
Malignant tumors are usually featured by several mutations
that accumulate during neoplastic proliferation (Hanahan and
Weinberg, 2011). It was therefore mandatory to assess the
eventual intervention of other mutated pathways. We therefore
selected 5 patients out of our series, including patient 12
initially negative for BRAF and NRAS mutations when screened
by four sequencing techniques. The nevus specimens were
sequenced using next-generation whole-exome analysis and
compared with the patient’s peripheral blood concomitantly
analyzed. This technique is currently the most powerful one to
assess the presence of any somatic mutation in an acquired
disease (Shyr and Liu, 2013). Surprisingly, the unique recurrent
mutation detected was NRAS. Patient 12, who was found
positive for an NRAS mutated subclone only after screening of 4
additional nevus areas using E-ice-COLD-PCR, also displayed
an NRAS clone (1 mutated tag in 79) in whole-exome
sequencing, consistent with the fact that a minor NRAS
mutated clone existed in this case.
Our study focuses on exonic regions, and further studies
are needed to assess that intronic mutations are not involved.
Indeed, exome sequencing only allows the identification of
somatic mutations present in coding areas. Our study does
not provide information concerning intronic regions, nor was
it conducted in a way to analyze the significance of germline
mutations. Nevertheless, Kinsler et al. (2012) have reported a
role for germline MC1R genotype in CMNs, dismissing MC1R
as a somatic mosaic candidate. Exome sequencing cannot
depict DNA copy number changes such as microdeletions or
duplications. These request performing comparative genomic
hybridization array. However, previous studies from Bastian
(2003) and Bastian et al. (1999) have indicated the absence of
such abnormalities in congenital nevi and acquired nevi,
except in Spitz nevi. Altogether, our data combined with
these other results indicate that no other somatic event than
the NRAS mutation at codon 61 is responsible for the
development of congenital nevi to the exclusion of possible
intronic mutations. Of note, other examples showed that
tumors including malignant ones may rely on a unique muta-
tion. Indeed, in rhabdoid child tumors, exome sequencing
analysis indicated that biallelic loss of a subunit of the SWI/
SNF chromatin remodeling complex was solely responsible
for this malignancy (Lee et al., 2012). Moreover, the recent
demonstration that identical somatic codon 61 NRAS
mutations were found in different CMN lesions, melanomas
as well as in neurological lesions from the same patients, also
supports the causative role of the NRAS mutation in CMN
genesis (Kinsler et al., 2013). In the same study, Kinsler et al.
(2013) report that the NRAS mutation found in affected
patients segregated only in neural crest–derived cells or
tumors such as choroid plexus papilloma, neurocristic hamar-
toma, meningioma, or diffuse leptomeningeal melanocytosis
as the same NRAS mutation was found in these separate
anatomical sites. Conversely, NRAS mutation was absent
from other tissues such as the blood of patients. This supports
the hypothesis of a single-mutated precursor cell giving rise to
the nevus as well as rare neural crest–derived tumors.
We report BRAF mutations in 5.2% (1/19) and 30% of
large–giant and small–medium CMNs, respectively. Previous
studies found conflicting data indicating the presence of a
BRAF mutation between 0% (Bauer et al., 2007; Wu et al.,
2011) and 86% in nevi documented either at birth by parents
testimony (Ichii-Nakato et al., 2006), medical records (Wu
et al., 2007; Qi et al., 2011), or selected by histological criteria
(Pollock et al., 2003). Such histological selection is contro-
versial as it is known that acquired melanocytic nevi may
mimic histologically a congenital pattern. Using our sensitive
techniques with nevi assessed both by parents’ testimony and
medical records, we were able to find that the frequency of
BRAF mutation does not exceed 30%, showing that it was less
associated with CMN than NRAS mutation.
In our study, patients have been categorized using Ruiz-
Maldonado classification (Ruiz-Maldonado, 2004). The risk of
melanoma appears nearly absent in small and medium nevi
that have been grouped here. In contrast, malignant
transformation develops in up to 5% in series of nevi with
PAS 420 cm (Ruiz-Maldonado et al., 1992; Marghoob et al.,
1996). Importantly, in the literature, a precise estimation of
such risk is not known for the large nevi (410–20 cm) that we
have therefore grouped with the giant nevi (420 cm).
Interestingly, the rate of NRAS mutation appears similar in
these large (11/12, 92%) and giant (7/7, 100%) specimens.
CMNs may have different genetic signatures, with either
NRAS or BRAF mutations, BRAF mutations having a lower
incidence rate in CMN 420 cm PAS, and a higher incidence
rate in small CMNs. On the other hand, B79% (376 of 479)
of acquired nevi harbor BRAF mutations (Pollock et al.,
2003; Ichii-Nakato et al., 2006; Ross et al., 2011). Of note,
these acquired nevi do not transform more frequently than
melanocytes interspersed in normal epidermis outside a
nevus. Therefore, the risk of malignant transformation does
not parallel the expression of BRAF mutation. Interestingly,
as compared with BRAF mutated melanomas or NRAS/BRAF
WT melanomas, melanomas with NRAS mutations are more
likely to be thicker tumors and to have a higher mitotic rate
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(Devitt et al., 2011; Ascierto et al., 2013). One may therefore
consider that BRAF mutations may not be as important as
NRAS mutations in the risk of melanoma arising from benign
nevi in general and CMNs in particular. Nevertheless, in order
to fully answer that question, studies comparing melanoma
incidence rate in NRAS mutated CMNs and in BRAF mutated
CMNs would be needed.
In conclusion, our study strongly suggests that codon 61
NRAS mutations in melanocytes are sufficient to drive in utero
proliferation. This result should encourage to examine alter-
native medical treatments to surgery.
MATERIALS AND METHODS
Study approval
The study was approved by the institutional independent ethics
committee (Comite´ de Protection des Personnes Ile-de-France V)
and complied with the Declaration of Helsinki Principles.
The patients’ guardians provided written informed consent before
their participation.
Subjects
Clinical phenotyping was performed by AP, NK, and SG. Classifica-
tion was done using the PAS of the largest lesion (Ruiz-Maldonado,
2004). A total of 19 patients with large or giant CMNs and 20 patients
with small or medium CMNs were included prospectively in the
study and nevus samples collected. Tumor tissues and matched blood
from five patients diagnosed with large or giant CMNs were collected
for the whole-exome sequencing analysis.
DNA extraction and genotyping
DNA was extracted using standard techniques: from fresh tissue using
the DNeasy Blood and Tissue Kit (Qiagen, Courtaboeuf, France) and
from paraffin-embedded tissue using QIAamp DNA FFPE Tissue Kit
(Qiagen, France). The DNA was quantified using a NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington,
DE). Several genotyping methods were used to identify BRAF exon 15
and NRAS exons 2 and 3 mutations using specific primer sets.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were
used for control of DNA quality. Positive, negative, and no-DNA
controls were included in each run.
Sanger sequencing
A sequence of B500 nucleotides surrounding the mutation site was
amplified using the Finnzyme Phusion High-Fidelity DNA polymerase
(Thermo Scientific, Villebon-sur-Yvette, France). Depending on the
CG content of the amplified sequence, DMSO was added to the
reaction. PCR products were then purified on 96-well Multiscreen-
PCR filtration plates (Millipore, Molsheim, France). The following
NRAS and BRAF primers were used: BRAF_F, 50-TGCTCTGATAGG
AAAATGAGATCTAC-30 and BRAF_R, 50-GGCCAAAAATTTAATCAG
TGG-30; NRAS2_F, 50-GAACCAAATGGAAGGTCACA-30 and
NRAS2_R, 50-TGGGTAAAGATGATCCGACA-30; NRAS3_F, 50-CCAG
ATAGGCAGAAATGGGCT-30 and NRAS3_R, 50-GCTCTATCTTCCCT
AGTGTGGT-30. A listing of the other primers used, annealing
temperatures, and expected length of PCR products is given in
Supplementary Table S1 online. Sanger sequencing analyses were
conducted according to the manufacturer’s protocol using respectively
the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems,
Courtaboeuf, France), on an ABI3130 running ABI Prism DNA
Sequence Analysis Software (Applied Biosystems).
Pyrosequencing
Pyrosequencing was performed according to standard procedures
using PyroMark Gold Q96 (Qiagen, Hilden, Germany) reagents and a
PyroMarkTM Q96 ID instrument. Pyrograms outputs were analyzed
with PyroMarkTM Q96 ID Software (Qiagen, Germany) using the
allele quantification mode.
High-resolution melting
HRM analyses were conducted according to the manufacturer’s
protocol using the LC480 HRM Scanning Master (Roche, Boulogne-
Billancourt, France) on a LightCycler 480 (Roche).
Enrichment of NRAS mutations by E-ice-COLD-PCR
For codon 61 NRAS mutation amplification, an E-ice-COLD-PCR assay
was designed following the standard protocol (How Kit et al., 2013).
PCR primers (NRAS_F 50-GTTGGACATACTGGATAC-30 and NRAS_R
Biotin-50-ATGACTTGCTATTATTGATG-30) were designed with
Beacon Designer 8 (Premier Biosoft, Palo Alto, CA) and purchased
from Biotez (Berlin, Germany). Primers amplified a 113-bp
PCR product flanking the codons of interest. The nonextendable
blocker probe of 50-nucleotide length (NRAS_BK_LNA 50-GATA
CAGCTGGAþCþAþAGAAGAGTACAGTGCCATGAGAGACCAA
TACATGAG-30-Phosphate), purchased from TibMolBiol (Berlin,
Germany), overlaps 5 nucleotides with the forward PCR primer and
presents a triplet of LNA residues centered on codon 61 in order to
improve the DTM of homoduplexes compared with heteroduplexes
when the mismatches are located on the three nucleotides of interest.
The critical temperature of 79 1C was determined as described in
How Kit et al. (2013) using a NRAS c.182A4G mutated cell
line (BLM melanoma cells) and WT DNA (Promega, Lyon, France).
E-ice-COLD-PCR reaction was performed in a Mastercycler Pro S
(Eppendorf, Le Pecq, France) and contained 5–25 ng of genomic
DNA, 1 HotStar Taq DNA polymerase Buffer, 1.6 mM of addi-
tional MgCl2, 200mM of dNTPs, 200 nM of each primer, 2 U of HotStar
Taq DNA polymerase (Qiagen, France), and 10–50 nM of Blocker
probe in a final volume of 25ml. An initial denaturation step was
performed for 10 minutes at 95 1C, followed by 6 cycles of standard
PCR (30-second denaturation at 95 1C, 20-second annealing at 55 1C,
and 10-second elongation at 72 1C) and 44 cycles of
E-ice-COLD-PCR (20-second denaturation at 95 1C, 30-second
blocker annealing at 70 1C, 20-second at 79 1C (critical temperature),
20-second primer annealing at 55 1C, and 10-second elongation
at 72 1C) to enrich the mutations. Mutation detection, identification,
and quantification were performed by pyrosequencing. Next, 10ml
of amplified E-ice-COLD-PCR products were purified and rendered
single-stranded on a PyroMark Q96 Vacuum Workstation (Qiagen,
France) as previously described (Tost and Gut, 2007). The sequencing
primer (NRAS_Gen_F, 50-TGGACATACTGGATACAGC-30) was
annealed to the target sequence after incubation at 80 1C for
2 minutes.
Sensitivity of the applied sequencing techniques
Using given amounts of mutated DNA as standards, the mutation
detection sensitivity for each of the applied sequencing techniques for
the BRAF and NRAS mutations is as follows: BRAF screening by
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Sanger, 15%; NRAS exon 2 and 3 screening by Sanger, 15%; NRAS
exon 2 and 3 screening by HRM, 5%; and NRAS exon 3 screening by
ice-COLD-PCR, 0.5–1%.
Whole-exome sequencing
Exome capture was performed using Agilent (Santa Clara, CA)
SureSelect Human All Exon 50 Mb according to the manufacturer’s
instructions. Briefly, 3mg of DNA from each sample was used to
prepare the sequencing library through shearing of the DNA followed
by ligation of sequencing adaptors. Whole-exome sequencing was
performed, and paired-end sequencing (2 76 bp) was carried out
using the Illumina (San Diego, CA) HiSeq 2000; the resulting data
were analyzed with the Illumina pipeline to generate raw fastq files.
The coverage of our samples varied between 51 and 54 .
Somatic mutation detection from whole-exome sequencing
After raw paired-end reads from whole-exome resequencing were
aligned/mapped to the human genome reference (hg19) and PCR
duplicate reads were removed by Mosaik aligner, we then analyzed
the resulting alignments using the Bayesian model-based software
GigaBayes/FreeBayes (National Institutes of Health, Bethesda, MD)
that enables the efficient analysis of billions of aligned short-read
sequences (Marth et al., 1999). The program evaluates each aligned
base and base quality value at each position to indicate putative
single-nucleotide variations (SNVs) and short insertions/deletions
(indels), and their corresponding SNV probability value. Base
quality values are converted to base probabilities corresponding to
each of the four possible nucleotides. Using a Bayesian formulation, a
SNV probability value (or indel probability value, as appropriate) is
calculated as the likelihood that multiple different alleles are present
between the reference genome sequence and the reads aligned at that
position. If the probability value exceeds a prespecified threshold, the
SNV or indel candidate is reported in the output. In this study, we
used a SNV probability cutoff value (0.9) to define a high-confidence
SNV or short indel candidate. We also filtered out all known SNVs/
indels in the University of California, Santa Cruz (UCSC) dbSNP 135
and 1000 human genome project SNP database, and kept any
mutations that are in the Catalogue of Somatic Mutations in Cancer
(COSMIC) database curated by Wellcome Trust Sanger Institute. We
then determined the somatic status of each SNV (or indel) by
comparing the genotypes and likelihood between matched normal
and tumor samples. The somatic status of a specific SNV/indel was
reported if the matched normal had wild allele–based homozygous
genotype and the tumor had heterozygous or mutant allele–based
homozygous genotype with a certain cutoff of genotype likelihood/P-
value (0.99). Finally, each somatic mutation or indel was annotated
with its functional effect by SIFT (http://sift.jcvi.org, J Craig Venter
Institute, San Diego, CA) to determine whether a mutation candidate
was synonymous or nonsynonymous (benign or deleterious). Five
nevus samples and five matched blood samples were processed and
analyzed using whole-exome sequencing (Otogenetics, Norcross,
GA). Library construction followed the procedure of previous pub-
lications (Stransky et al., 2011; Berger et al., 2011; Chapman et al.,
2011). Exome sequencing data were then validated by Sanger
sequencing and when necessary allele-specific PCR. The allele-
specific PCR approach was used to validate the 7 non-NRAS, non-
BRAF mutations using WT and mutant primer couples for each gene.
Primer annealing temperature was selected to allow WT allele
amplification with WT complementary primers and not with the
mutant complementary primer.
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